La Radiologia medica 2017 07 15() doi 10.1007/s11547-017-0791-1
To evaluate the clinical value of C-arm CT (CACT)-guided interstitial iodine-125 ((125)I) brachytherapy on pulmonary tumors.
MATERIALS AND METHODS
30 patients with 40 solid pulmonary tumors were enrolled to undergo CACT-guided interstitial (125)I brachytherapy between November 2011 and November 2014. The needle path was planned on a CACT virtual navigation and real-time fluoroscopy system. Technical success, puncture score, procedure time, local control rate (LCR), radiation exposure, complications and survival were investigated.
The technical success of interstitial (125)I brachytherapy under CACT guidance was 40/40 (100%). The performance score was 4.7 ± 0.5 with a mean total procedure time of 17.7 ± 5.6 min. LCR in small (≤2.0 cm), intermediate (2.1-4.9 cm) and large (≥5.0 cm) pulmonary tumors was 100, 89.5 and 72.7% at the 4-month follow-up, respectively. The mean effective dose was 10.1 ± 2.8 mSv. Major complications occurred in four patients (13.3%). The mean survival time was 28.4 ± 2.3 months.
CACT can provide virtual navigation and real-time fluoroscopy synchronously for interstitial (125)I seed implantation on pulmonary tumors.